Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation

Blood

Volumn 112, Issue 10, 2008, Pages 4024-4027

  Selleng, Sixten ^a   Haneya, Assad ^b   Hirt, Stephan ^b   Selleng, Kathleen ^a   Schmid, Christof ^b   Greinacher, Andreas ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; HEPARIN; HIRULOG; IMMUNOGLOBULIN G; LEPIRUDIN; PHENPROCOUMON; PROSTACYCLIN; THROMBOCYTE FACTOR 4; TIROFIBAN; ANTICOAGULANT AGENT; AUTOANTIBODY; HIRUDIN DERIVATIVE; PIPECOLIC ACID DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ANTICOAGULATION; ARTICLE; CARDIOGENIC SHOCK; CARDIOPULMONARY BYPASS; CASE REPORT; CONGESTIVE CARDIOMYOPATHY; DONOR; DRUG REEXPOSURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART TRANSPLANTATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTENSIVE CARE; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; BLOOD; CHEMICALLY INDUCED DISORDER; HEART FAILURE; IMMUNOLOGY; MIDDLE AGED; THROMBOCYTOPENIA;

ADULT; ANTICOAGULANTS; AUTOANTIBODIES; HEART FAILURE; HEART TRANSPLANTATION; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PIPECOLIC ACIDS; PLATELET FACTOR 4; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 58149160052     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-145243     Document Type: Article

References (21)

1. Koster A, Kukucka M. Anticoagulation of patients with heparin-induced thrombocytopenia in cardiac surgery. Curr Opin Anaesthesiol. 2004;17: 71-74.
2. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133: 340S-380S.
3. Nuttall GA, Oliver WC Jr, Santrach PJ, et al. Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg. 2003;96:344-350.
4. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.
5. Eichler P, Budde U, Haas S, et al. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost. 1999;81:625-629.
6. Juhl D, Eichler P, Lubenow N, et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol. 2006;76:420-426.
7. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759-765.
8. Greinacher A, Warkentin TE. Treatment of Heparin- Induced Thrombocytopenia: An Overview. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. New York: Informa Healthcare; 2007:283-317.
9. Lubenow N, Kempf R, Eichner A, et al. Heparininduced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest. 2002;122:37-42.
10. Arepally GM, Ortel TL. Clinical practice. Heparininduced thrombocytopenia. N Engl J Med. 2006; 355:809-817.
11. Lubenow N, Selleng S, Wollert HG, et al. Heparin- induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann Thorac Surg. 2003;75:577-579.
12. Pötzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med. 2000;343:515.
13. Selleng S, Lubenow N, Wollert HG, Müllejans B, Greinacher A. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin. Ann Thorac Surg. 2001;71:1041-1042.
14. Schroder JN, Daneshmand MA, Villamizar NR, et al. Heparin-induced thrombocytopenia in left ventricular assist device bridge-to-transplant patients. Ann Thorac Surg. 2007;84:841-845.
15. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. New York: Informa Healthcare; 2007:21-66.
16. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. New York: Informa Healthcare; 2007:227-260.
17. Janatpour KA, Gosselin RC, Dager WE, et al. Usefulness of optical density values from heparin- platelet factor 4 antibody testing and probability scoring models to diagnose heparin-induced thrombocytopenia. Am J Clin Pathol. 2007;127: 429-433.
18. Schenk S, El Banayosy A, Morshuis M, et al. IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support. J Thromb Haemost. 2007;5:235-241.
19. Greinacher A, Juhl D, Strobel U, et al. Heparininduced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost. 2007;5:1666-1673.
20. Dellaria SM, Greilich PE, Sarode R. Urgent cardiac surgery in a patient with a remote history of heparin-induced thrombocytopenia: use of the anti-PF4/heparin ELISA confirmatory test. Anesth Analg. 2008;107:379-381.
21. Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/ platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 2008;100:678-684.